



General Information

MAGICBULLET consortium and scientific committee of the 5th International CeBiTec Research Conference:

Cesare **Gennari** (Università degli Studi di Milano, IT)
Pirjo **Laakkonen** (University of Helsinki, FI)
Gábor **Mező** (Eötvös Loránd University Budapest, HU)
Ines **Neundorf** (University of Cologne, DE)
Andreas **Pahl** (Heidelberg Pharma GmbH, Ladenburg, DE)
Jan **Anderl** (Heidelberg Pharma GmbH, Ladenburg, DE)
Umberto **Piarulli** (Università degli Studi dell' Insubria, IT)
Norbert **Sewald** (Bielefeld University (Co-ordinator), DE)
Christian **Steinkühler** (Exiris, Rome, IT)
József **Tóvári** (National Institute of Oncology, Budapest, HU)

Registration

For details regarding registration please visit www.magicbullet.de

Location

Center for Interdisciplinary Research (ZiF)
Methoden 1, 33615 Bielefeld
<http://www.uni-bielefeld.de/ZiF>

Accommodation

You are encouraged to book your accommodation in the Park Inn conference hotel, which provide special rates for conference participants. Please make your reservations mentioning group reference **24421** at

Park Inn by Radisson Bielefeld
Telephone: +49 521 9238-0
Fax: +49 521 9238-250
Email: info.bielefeld@eventhotels.com

Further Information


For further information please contact drugconjugates2015@uni-bielefeld.de




Arrival

By car, you can take the A2 Dortmund - Hannover, exit at "Bielefeld-Zentrum", follow the street signs towards the center ("Zentrum"), and from there follow the signs to "Werther". From the "Wertherstraße", the ZiF is on the left side on the slope of the hill. The entrance is signposted.

Bielefeld can be reached from any major town by trains running on an hourly schedule (Eurocity train system: marked EC, IC, or ICE on the train schedule). From Bielefeld's main station you can either take a taxi to the ZiF (approx. EUR 10,-) or take the underground tram line 4 (destination "Universität" or "Lohmannshof"). From the tram stop "Universität" you can reach the ZiF by walking up the hill behind the main building of the university (the way is signposted).



Drug Conjugates for Directed Therapy



September 20th – 23rd, 2015

Center for Interdisciplinary Research (ZiF)
Bielefeld University, Germany



Invitation

The Center for Biotechnology (CeBiTec) of Bielefeld University cordially invites you to attend the 5th International Bielefeld-CeBiTec Research Conference on "Drug Conjugates for Directed Therapy". The conference will be held at the Center for Interdisciplinary Research (ZiF) of Bielefeld University from **September 20th to 23rd, 2015**.

CeBiTec Research Conferences are annual events with thematic focus on a challenging topic in the life sciences. The 2015 conference Drug Conjugates for Directed Therapy is being organized by the Marie Skłodowska-Curie European Training Network **MAGICBULLET** (www.magicbullet.de), which is currently being funded by the EU in the Horizon 2020 Framework Programme for Research and Innovation.

The scope of the CeBiTec Research Conference will include:

- Antibody-Drug Conjugates
- Peptide-Drug Conjugates
- Targets and Specificity
- New Drugs
- Linker Technologies
- Applications
- Process Development

The meeting will feature plenary lectures, poster presentations and short presentations.

We look very much forward to welcome you in Bielefeld!

The conference committee



Programme

Confirmed plenary speakers

Jan Anderl Heidelberg Pharma, DE
Antibody-Drug Conjugates targeting RNA polymerase II

James Baker University College London, UK
The Next Generation Maleimide platform for the construction of homogeneous protein conjugates

Annette Beck-Sickinger Leipzig University, DE
Targeted cancer diagnosis and therapy with peptide conjugates

Ravi J. Chari ImmunoGen, Waltham, US
Antibody-Drug Conjugates: Pathway from a concept to the clinic

Donald M. Engelman Yale University, US
pHLIP® targeting and delivery of PNA in vivo to silence microRNA in acidic tumor cells

Cesare Gennari Università degli Studi di Milano, IT
Tumor targeting via integrin ligands: Synthesis and biological evaluation of RGD peptidomimetic-Paclitaxel conjugates

Ulf Grawunder NBE Therapeutics, CH
SMAC-Technology – generation of site-specifically conjugated ADCs by highly efficient enzymatic conjugation

Nicolas Joubert Université de Tours, FR
A new chemical platform for the modular construction of homogeneous Antibody-Drug Conjugates

Horst Kessler TU München, DE
Selective addressing integrin subtypes for drug research, molecular imaging and biophysical studies

Felix Kratz CytRx Corporation, DE
Albumin-based drug delivery systems in oncology: From bench to bedside

Pirjo Laakkonen Biomedicum Helsinki, FI
Peptide-based tumor targeting

Maxime Lampilas Sanofi, Vitry sur Seine, FR
Process development of SPDB/DM4 conjugates



Programme

Hans-Georg Lerchen Bayer, DE
Targeted drug conjugates: Challenges in the interface between small molecules and proteins

Marilena Manea University of Konstanz, DE
Drug delivery systems containing GnRH-III peptide as a targeting moiety

Gábor Mező MTA-ELTE, HU
Dual targeting with cyclic NGR peptides

Ines Neundorff University of Cologne, DE
Organometallic bioconjugates: synthesis, cellular uptake and biological activity

Umberto Piarulli Università degli Studi dell'Insubria, IT
Synthesis and biological evaluation of integrin and dual integrin-VEGFR ligands for tumor targeting therapy

Doron Shabat Tel Aviv University, IL
tba

József Tóvári National Institute of Oncology, HU
Application of peptid-drug conjugates in animal tumor/metastasis models

Fred Valeriote Henry Ford Health System, Detroit, US
Discovery of anticancer leads as potential drug conjugates

Acknowledgements

This project has received funding from the **European Union's Horizon 2020 research and innovation programme** under the Marie Skłodowska-Curie grant agreement No 642004.

